The Gastroenterology Regulatory Endpoints and the Advancement of Therapeutics VI Workshop, held on July 22, 2021, provided a forum for patients and representatives from academia, industry, patient advocacy groups and FDA to discuss drug development for celiac disease (CeD). The workshop focused on the approach to histologic assessments in clinical trials, considerations for pediatric drug development, and use of a gluten challenge (GC) in clinical trials. Given that no histologic scoring system is widely accepted for use in clinical trials at this time, early phase clinical trials should ideally explore a variety of histologic scales and assess the histologic findings of celiac disease as individual measures to inform future trials. When planning pediatric drug development in CeD, appropriate use of extrapolation of efficacy data from adequate, well-controlled studies in adults could facilitate timely access to safe and effective therapies for pediatric patients. Identification of a fit-for-purpose pediatric clinical outcome assessment could further advance pediatric drug development.

Histologic responses to the GC depend on exposure dose and duration; short exposures do not appear to cause long-term consequences. However, the GC should be incorporated into clinical trials in a thoughtful manner to generate interpretable results and ensure patient safety. Ongoing collaboration between all stakeholders will facilitate the development of safe and effective therapeutics for CeD.The pandemic caused by SARS-CoV-2 has drastically changed the global health landscape. Our objective was to verify if, after the start of the pandemic, there was an increase in in-hospital mortality in patients admitted to a Gastroenterology Service of a 3rd level hospital.

Visit for more related articles at Journal of Medical Research and Health Education

Kindly submit your article through Editorial Tracking or through medresearch@echemistry.org

With Regards
Sofia
Journal Co-ordinator
Journal of Medical Research and Health Education